Pfizer announced on December 13 that the FDA has approved Ixifi, PF-06438179, infliximab-qbtx, the company’s second biosimilar to the reference infliximab, Remicade.
Pfizer announced on December 13 that the FDA has approved Ixifi, PF-06438179, infliximab-qbtx, the company’s second biosimilar to the reference infliximab, Remicade.
Approval of the biosimilar follows acceptance of Ixifi’s Biologics License Application (BLA) in April 2017, and is based on the totality of evidence demonstrating a high degree of similarity to the reference Remicade. Pfizer’s BLA included data from the REFLECTIONS B537-02 study in patients with moderate to severe rheumatoid arthritis (RA).
The phase 3, multi-national, randomized, double-blind, 2-arm, parallel-group study evaluated the safety, efficacy, and immunogenicity of the biosimilar compared with the reference infliximab administered intravenously in combination with methotrexate. The study met its primary endpoint of achieving a response of ACR20—a 20% improvement by American College of Rheumatology criteria—at week 14. These findings were supported by additional data at week 30.
The FDA has approved Ixifi as a treatment for patients with RA, Crohn disease, pediatric Crohn disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Pfizer adds Ixifi to its portfolio of biosimilars, including Inflectra, the first FDA-approved biosimilar infliximab, as well as European Medicines Agency- (EMA) approved Retacrit (epoetin zeta), and EMA-approved Nivestim (filgrastim). However, a Pfizer representative told The Center for Biosimilars® that the company does not plan to commercialize Ixifi in the United States. Pfizer will continue to market its first infliximab biosimilar, Inflectra, in the US market, said the representative, and the approval of Ixifi will not impact its strategy with Inflectra.
Inflectra has had a challenging experience in the US market; while Pfizer’s first FDA-approved infliximab biosimilar has launched in the United States, Johnson & Johnson’s strategies to protect its market share have led Pfizer to file suit against the reference product’s sponsor, claiming that anti-competitive practices have effectively denied patients access to lower-cost biosimilars.
Sandoz, which acquired the European rights to Ixifi in 2016, plans to develop and eventually commercialize the drug in the 28 EU member states as well as Iceland, Liechtenstein, and Norway.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.